An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa by Lieketseng J Masenyetse et al.
Masenyetse et al. AIDS Research and Therapy  (2015) 12:6 
DOI 10.1186/s12981-015-0044-0RESEARCH Open AccessAn assessment of adverse drug reactions among
HIV positive patients receiving antiretroviral
treatment in South Africa
Lieketseng J Masenyetse1,2, Samuel OM Manda1,2* and Henry G Mwambi2Abstract
Background: Antiretroviral treatment (ART) has been effective in reducing HIV/AIDS related morbidity and
mortality. However, the use and uptake of ART has resulted in adverse reactions, due mainly to the medicine’s
toxicity and interactions with other medicines. The timing of adverse drug reactions (ADRs) among these patients is
a critical public health issue for antiretroviral (ARV) treatment adherence and retention. Reliable monitoring of HIV
patients on ART is through a structured pharmacovigilance surveillance system. However, recurrent nature of these
data pose challenges in their analyses. This study aimed at modelling the timing of ADR events in HIV patients on
ART using correlated time-to-event models.
Methods: The data concern 590 HIV patients registered onto the Medunsa National ARV Pharmacovigilance
Surveillance System within 6 months of ART initiation between February 2007 and July 2011. Recurrent times of
ADRs and baseline characteristics: patient gender, and age, ART regimen, clinic and initiation period were extracted
from the data. The recurrent ADR events data were modelled using both shared frailty and marginal models on
the five patients’ characteristics as covariates.
Results: Out of 590 patients, 67% were female, 68% started on regimen: Stavudine, Lamivudine and Efavirenz; 37% had
experienced at least one ADR and 67% started ART in 2009–2011. Age (p-value = 0.0210), clinic (p-value < 0.0001) and
period of ART initiation (p-value = 0.0002) were significantly associated with timing of first ADR. There was a significantly
higher rates of ADR recurrences in patients aged 38–44 years [HR = 2.45; 95% CI = (1.47; 4.10)] vs. 30 years and less,
patients taking regimen: Zidovudine, Lamivudine and Nevarapine) vs. regimen: Stavudine, Lamivudine and Efavirenz
[HR = 2.09; 95% CI = (1.35; 3.22)], while the rate was lower among those who started ART in 2009–2011 vs. those who
initiated in 2007–2008 [HR = 0.55; 95% CI = (0.40; 0.76)].
Conclusion: More realistic time-to-event models for recurrent events data have been used to analyse timing of ADR
events in HIV patients taking ARV treatment. Age, antiretroviral regimen type and period of initiation of ART were
associated with the timing of HIV/AIDS drug related adverse reactions regardless of the analysis model used. This study
has public health policy implications in addressing the added morbidity among HIV patients taking ARV treatment in the
context of universal scaling up of ARV treatment.
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The Human Immunodeficiency Virus (HIV) has changed
from life threatening to chronic condition due to the
almost universal use and accessibility of antiretroviral treat-
ment (ART) among HIV patients [1]. Antiretroviral (ARV)
treatment works by providing suppression of viral load and
restoring the immune system. It is estimated that out of
the 35.3 million people living with HIV worldwide, 10.6
million were receiving ART in 2012 [2]. Nearly, 6.6 million
HIV/AIDS related deaths worldwide have been prevented
as a result of ART [2]. Despite these gains, adverse reac-
tions to these medicines remain a significant public health
concern and may compromise the effectiveness of the ART
programmes [3,4].
The risk of adverse drug reactions (ADRs) arises because
of the effect of the disease on the immune systems and the
safety profiles of the complex ART drugs [3]. There
are a number of ADRs related to ART that have been
documented, and may be mild to severe; and short to
long term depending on the environment [1,5-12].
ADRs in developing countries may differ from those
in developed countries because of high prevalence of
conditions such as malnutrition, tuberculosis and patients
presenting with advanced HIV disease [13]. For instance,
it has been found that in Africa, neuropathy, neutropenia
and lipodystrophy are the predominant ADRs [14]. Short
term ADRs are a potential threat to successful initiation
and adherence to ART [15]. The timing of ADRs may also
depend on the type of drugs. Studies have shown that
patients on Efavirenz, Lamivudine and Zidivudine or
Indinavir, Zidovudine and Lamivudine may present with
ADRs within the first 12 or 24 weeks, respectively [16,17].
ADRs may be common or specific to class of drugs
[1,8,15]. Drugs classified as non-nucleoside reverse
transcriptase inhibitors (NNRTIs) which include Efavir-
enz (EFZ) and Nevirapine (NVP) are known to cause
rashes and hepatotoxicity. On the other hand drugs
classified as nucleoside reverse transcriptase inhibitors
(NRTIs) including Zidovudine (AZT) and Stavudine
(d4T) are known to cause anemia, nausea, rashes,
lipoatrophy and lactic acidosis [1].
Apart from ADR depending on the environment and the
type of ART regimen, a number of other risk factors have
been identified, that include patient age, gender, duration
on treatment, disease biomarkers such as CD4 count and
viral load and body mass index (BMI) [7,10,18,19]. These
risk factors have been found to interact with type of ADR.
For instance females are more likely to develop rashes and
hepatotoxicity [7,18]; and patients aged 40 years and above
are at a higher risk of developing peripheral neuropathy
when taking d4T [10]. The longer a patient is on ART the
less likely they would experience ADRs; possibly as a result
of stability in ARV regimen, coming after many changes
and eventually settling on an acceptable regimen [19].Monitoring safety and toxicity related to ART remains a
challenge facing the public health sector. Monitoring is
usually done using spontaneous surveillance of HIV pa-
tients on treatment. Spontaneous reporting of ADRs is a
very inefficient system in detecting drug-related conditions,
leading to underestimation of the burden due to ADRs
[3,20,21]. Thus, more systematic and more robust surveil-
lance methods including structured surveillance pharma-
covigilance systems, which assesse and monitor safety
profile and impact of antiretroviral medicines have been
advocated [4]. Structured surveillance tracks HIV positive
patients who are on ART to assess drug related morbidity
and mortality over time. South Africa, a country heavily hit
by the HIV epidemic, uses spontaneous surveillance of
HIV patients on ART to assess ART-related adverse effects.
Though these data are routinely available, the coverage of
important patient data may not be adequate. Thus, for the
purposes of this study, data from a structured surveillance
system in South Africa are used.
The adverse drug reaction events in patients often are
of recurrent nature, such that the repetitions tend to
cluster more in some patients than in others. Analyses
of these data are complicated due to the fact that inde-
pendence between the recurrent event times cannot be
assumed in a subject. In medical studies, time-to-event
models have been developed to account for possible de-
pendence between recurrent events data [22,23]. The
aim of this paper was to provide a unified analysis of re-
current ADR events data from a structured antiretroviral
pharmacovigilance surveillance system. The authors are not
aware of any such study that has comprehensively analysed
data from this kind of structured surveillance system for
HIV positive patients. A previous study investigated ADRs
in a sample of adult inpatients at a local hospital in South
Africa, and compared the distribution between HIV and
non-HIV patients [21]. This present study is very specific
and unique by assessing ARV-related ADRs in a cohort of
only HIV patients in a country with one of the highest HIV
burden of the disease and with over 75% of the 6.1 million
HIV patients on free ART [24].
Methods
Data
Data are from the Medical University of South Africa
(MEDUNSA) National ARV Pharmacovigilance Centre,
which is based at the University of Limpopo MEDUNSA
campus. Recruitment of patients started in January 2007
from four clinics, two in Gauteng, one in Limpopo and
one in Mpumalanga provinces. Patients were followed up
to obtain information on the ADRs they were experiencing
and these data were collected during patients’ clinic visita-
tions. Other information contained in the data were the
type of regimens patients were taking together with the
dates when they switched or collected the same regimens.
Table 1 Patients demographic and baseline characteristics,
HIV Patients on ART, South Africa 2007-2012







Overall 590 (100) 217 (100) 61 (100) 24 (100)
Gender
Male 192 (33) 61 (28) 16 (26) 5 (21)
Female 398 (67) 156 (72) 45 (74) 19 (79)
Age at clinic visit
30 and less 87 (15) 22 (10) 2 (3) 0 (0)
31 – 37 183 (31) 64 (29) 14 (23) 5 (21)
38 – 44 154 (26) 70 (32) 24 (39) 10 (42)
45+ 166 (28) 61 (28) 21 (34) 9 (37)
Clinic
Clinic A 188 (32) 32 (15) 5 (8) 1(4)
Clinic B 31 (5) 4 (2) 0 (0) 0 (0)
Clinic C 318 (54) 162 (75) 48 (79) 19 (79)
Clinic D 53 (9) 19 (9) 8 (13) 4 (17)
ART regimens
1a (d4T, 3TC, EFZ)* 402 (68) 144 (66) 38 (62) 12 (50)
1b (d4T, 3TC, NVP)* 67 (11) 20 (9) 3 (5) 1(4)
1c (AZT, 3TC, EFZ)* 46 (8) 25 (12) 12 (20) 4 (17)
Others 75 (13) 28 (13) 8 (13) 7 (29)
Year started ART
Before 2009 194 (33) 94 (43) 40 (66) 21 (88)
2009 and after 396 (67) 123 (57) 21 (34) 3 (13)
*d4T = Stavudine; 3TC = Lamivudine; EFZ = Efavirenz; NVP =Nevarapine;
AZT = Zidovudine.
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found in Dube et al. [9].
The study included HIV positive patients aged 15 years
and above, receiving ART in the South Africa public
health sector [9]. Patients who met the inclusion criteria
were recruited when visiting public health sector clinics
using systematic random sampling. Patients who agreed
to participate in the study were asked to sign consent
forms. Patients who were antiretroviral naïve or on ART
at private clinics were excluded from the study. Further
details about the study can be found in Dube et al. [9].
For purposes of this paper, data were restricted only to
590 patients enrolled within 6 months of their ART
initiation between January, 2007 and August, 2011. The
covariates considered in this analysis were age, gender,
clinics and antiretroviral medication patients are taking.
Statistical analysis
In previous analyses of these types of data, standard
logistic and survival models, assuming ADR events as
independent, were fitted [20,21]. For this study ADR
recurrent events in a patient could not be taken to be
independent of each other: some patients could have
been more prone to experience ADRs than others. Thus
analyses of these data must take into account; possible
dependence in the occurrence of ADRs. This study used
more robust modelling techniques based on time-to-
event models for correlated survival data. In particular,
the marginal and shared frailty models were used to
model the recurring ADR events data in order to take
account of possible correlation between the data [22,23].
There are some analytical assumptions differentiating
the two proposed correlated survival models. The marginal
model fits separate failure times using survival models,
while the dependence structure unspecified but inflates the
estimated variance-covariance parameters of regres-
sion coefficients [23]. Under the shared frailty model
subject-specific random effects, which capture dependence
in the failure times within a subject, are assumed to be
time constant and independent and identically distributed
from a known distribution function. This can be relaxed to
have the subject-specific random effects to be time-
varying as in Manda and Renate [22] and to be dis-
tributed nonparametrically as in Manda [25]. The fitting
of the models were implemented in STATA version 12 as
described in Cleves and StataCorp [26].
Results
Descriptive analyses using summary statistics was under-
taken. These are shown in Table 1 for patients demographic
and baseline characteristics. A majority of the patients were
females accounting for 67% of the sample. Majority of the
patients were from clinic A and clinic C accounting for
about 86% of the sample, with 67% of the patients havingstarted ART from 2009. Overall 217 (37%) patients out of
590 experienced at least one ADR, most of them being fe-
males (72%), in Clinic C (75%), were on regimen 1(a) (66%)
at the time of reporting these ADRs and had started ART
from 2009. Of the 217 patients who had experienced at
least one ADR, 61 (28%) patients had ADRs for the second
time. Among patients experiencing a second ADR, a major-
ity were females (74%), were still in regimen 1a (62%), were
in the age group of 38 to 44 years (39%) and had started
ART before 2009 (66%).
Distribution of the observed ADRs is shown in Figure 1.
There was a total of 454 ADRs for all the 217 patients
who had experienced at least one ADR. Neuropathy
accounted for 20% of all ADRs followed by rash/skin
eruptions at 15%. Cough was also prevalent accounting
for 12% of the ADRs. Other ADRs accounting for 16% of
the total included those with proportions less than 2%,
such as acidosis, dermatitis, oedema and hypothyroidism.
In order to investigate associations between the different
covariates and timing of ADRs, Kaplan-Meier survival















Types of adverse drug effects
Figure 1 Distribution of adverse drug reactions among HIV patients on ART, South Africa 2007–2012.
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the curves between categories of the respective covariates
on timing to first ADR event. The survival curves with
the log-rank test are shown in Figures 2a-2e. Males
had better survival of not experiencing ADRs com-
pared to females, though the association was not sig-
nificant (log rank test = 0.1423). Age had a significant
effect on timing of experiencing first ADRs ( log rank
test = 0.0210), with patients aged less than 30 years
having lower ADR rates compared to those in older age
groups. Clinic and year patients initiated ART also had
significant effects on the timing of experiencing ADRs
(p-value ≤ 0.05) the first time.
The multivariate analyses included all the covariates
regardless of significance of associations from the univariate
log-rank test in the preceding paragraph. In terms of
modelling specific transitions between (from baseline to
first, from first to second, from second to third and so
forth) ADRs only the two transitions (baseline to first and
first to second timings) were used. The later transitions had
very few events of experiencing ADRs. We intially took
these as two independent time-to-event processes, and thus
can be modelled using standard proportional hazards
models. The adjusted results from fitting these are shown
in columns two and three of Table 2 on the hazard ratio
(HR) scale. Using of separate transitions as independent
was corrected by using all ADR events in a subject. These
were fitted using both the marginal and frailty models as
described in the Methods section. The adjusted results of
these later two models are presented in the last two col-
umns of Table 2, also on the HR scale.
The rate of experiencing first and second ADRs
were higher for females compared to males thoughnot significant, [Hazard ratio = 1.13; 95% Confidence
Interval = (0.82; 1.55)] and [HR = 1.32; 95% CI = (0.72; 2.42)]
respectively. Older age groups had higher rate of experien-
cing ADR compared to the younger age group of 30 years
and less, with significant risks being for patients in aged 38
– 44 years [HR = 1.83; 95% CI = (1.12; 3.01)]. Patients who
were in regimen 1(c) had significantly higher risks of having
an ADR compared to those in regimen 1(a) [HR = 1.86;
95% CI = (1.20; 2.87)]. Patients on regimen 1b had a
lesser rate of experiencing recurrent ADRs compared to
those in regimen 1a though this was not significant [HR =
0.65; 95% CI = (0.19; 2.21)].
The marginal model results indicate that patients in age
38 – 44 years and from 45 years had significantly higher
rate of recurrence of ADRs compared to those 30 years and
younger [HR = 2.45; 95% CI = (1.47; 4.10)] and [HR = 2.02;
95% CI = (1.16; 3.51)] respectively. Patients on regimen 1(c)
had significantly higher hazards of recurrence of ADRs
compared to patients on regimen 1(a) [HR = 2.09; 95% CI
= (1.35; 3.22)]. Patients who initiated ART from 2009
had significantly lower hazards of recurrence of ADRs
compared to patients who initiated ART before 2009
[HR = 0.55; 95% CI = (0.40; 0.76)].
Frailty model results show that 31 years and older
patients experienced higher rates of ADRs compared to
those aged 30 years and less. Patients who were initiated
ART from 2009 had significantly lower risks of recurrence
of ADRs compared to patients who were initiated before
2009 [HR = 0.90; 95% CI = (0.70; 1.16)], though this finding
was not significant. Patients attending clinic C and D had
significantly higher rate of recurrence of ADRs compared
to patients in clinic A [HR = 2.07; 95% CI = (1.29; 3.32)]
and [HR = 1.80; 95% CI = (1.11; 2.93)] respectively.
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Figure 2 Kaplan Meier curves for time to first ADRs among HIV patients on ART, South Africa 2007–2012 classified by (a) gender,
(b) age, (c) clinic (d) regimen and (e) Year started ART. HIV.
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regression where the outcome was categorized as 1 if a
patient had an ADR and 0 otherwise. The substantive
results were the same as those obtained using survival
models. Using logistic regressions models this way does not
account for possible correlation between recurrent ADRs,
Additionally, exposure time is not taken into account in the
logistics regression models, in contrast to time-to-event
models described in the preceding sections.
Discussions
This study has shown the utility of using correlated
survival models to the analysis of recurrent adverse drug
reactions events to account for possible dependence in
the events. The models have been applied to a very
important data based on structured surveillance of HIV
patients on antiretroviral treatment in South Africa. The
country has the largest number of people living with the
HIV virus and on ART in the world. Age, gender, ARVregimen type, period of initiation of ART were found to
be associated with the timing of HIV/AIDS drug related
adverse reactions regardless of the analysis model
used, though gender was not statistically significant.
The highly prevalent ADRs included neuropathy, rash,
cough and lipodystrophy, comparable with results
found in Nwokike [14]. As in Reddenna et al. [6],
neuropathy was the most prevalent adverse drug reac-
tion condition.
Patients older that ages 38 years experienced significantly
higher recurrence of ADRs compared to patients aged
30 years and less, which supports the findings previous
studies [7,19]. Gender differentials were also found with
females having higher risks of ADRs than males. Though
not statistically significant, the finding of gender differences
in experiencing ARV-related ADRs has been observed in
other African settings [18,19,27].
Patients taking AZT + 3TC +NVP combination had
higher rates of ADRs compared to patients on d4T +
Table 2 Adjusted Hazard Ratios (HR) of various characteristics on the occurrence of ADRs, HIV Patients on ART,
South Africa 2007-2012
1st ADR 1st ADR→ 2nd ADR Marginal model Frailty model
Characteristic HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Gender
Male 1 1 1 1
Female 1.13 (0.82, 1.55) 1.32 (0.72, 2.42) 1.23 (0.88, 1.72) 1.23 (0.94, 1.62)
Age
30 and less 1 1 1 1
31 – 37 1.33 (0.81, 2.19) 2.41 (0.54, 10.69) 1.59 (0.95, 2.66) 1.51 (0.94, 2.43)
38 – 44 1.83 (1.12, 3.01)* 3.19 (0.73, 13.93) 2.45 (1.47, 4.10)* 2.07 (1.29, 3.32)*
45+ 1.43 (0.85, 2.42) 3.23 (0.73, 14.29) 2.02 (1.16, 3.51)* 1.80 (1.11, 2.93)*
Clinic
Clinic A 1 1 1 1
Clinic B 0.77 (0.27, 2.20) - 0.73 (0.25, 2.11) 0.78 (0.28, 2.22)
Clinic C 3.74 (2.54, 5.50)* 2.36 (0.89, 6.22) 4.03 (2.75, 5.91)* 3.20 (2.24, 4.57)*
Clinic D 1.99 (1.10, 3.58)* 2.76 (0.85, 8.99) 2.14 (1.12, 4.09)* 1.96 (1.18, 3.25)*
ART regimens
1a (d4T, 3TC, EFZ) 1 1 1 1
1b (d4T, 3TC, NVP) 1.01 (0.61, 1.66) 0.65 (0.19, 2.21) 1.08 (0.65, 1.80) 0.99 (0.64, 1.55)
1c (AZT, 3TC, EFZ) 1.86 (1.20, 2.87)* 1.83 (0.91, 3.69) 2.09 (1.35, 3.22)* 1.83 (1.27, 2.62)*
Others 1.00 (0.65, 1.54) 1.18 (0.50; 2.82) 1.35 (0.90, 2.01) 1.43 (0.99, 2.04)
Year started ART
Before 2009 1 1 1 1
2009 and after 0.78 (0.58, 1.06) 0.41 (0.23, 0.74)* 0.55 (0.40, 0.76)* 0.90 (0.70, 1.16)
*Statistically significant at p-value ≤ 0.05.
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d4T + 3TC +NVP experienced higher rates of ADRs
compared to patients taking d4T + 3TC + EFZ. These
findings confirm previous ARV-related ADR data in
Spaulding et al. [28] and Webster et al. [29]. Due to high
rates of ARV-related ADRs, South Africa patients are
now using Tenofovir (TDF) containing regimen as a first
line ARV treatment. Depending on the prognosis,
AZT + 3TC +NVP and then d4T + 3TC + EFZ/NVP are
offered [30]. More pharmacovigilance studies are needed
to compare ADRs among patients on TDF containing
regimen with patients on AZT+ 3TC +NVP, a regimen
found with lower ADR rates in this study. Patients who
started ART after 2009 had a lesser rate of occurrence of
ADRs; this may be due better care and management of
HIV treatment.
This study showing high rates of ARV-related adverse
drug reactions has highlighted the added morbidity
among HIV patients taking ARV treatment. As indicated
in Mehta et al. [21] in contract to other ADRs, almost all
ARV-related ADRs are often inevitable and unpredictable,
which makes treatment of these ADRs problematic. This
creates extra cost burden to most public health systemsthat are stretched over many important health problems.
In terms of policy implication, a better understanding,
timely and proactive pharmacovigilance surveillance and
reporting, especially of problematic regimen and patients
subgroups, of ARV-related ADRs is advisable [4].Limitations of the study
The findings from this study should be interpreted
within caution. The surveillance data that was used
did not have grading of the severity of ADRs. Some
studies have graded the ADRs using the World
Health Organization grading or the Hartwig scale to
determine the level of severity to patients’ morbidity
[10,19,31,32]. Not all the data in the database were used as
some patients were registered into the surveillance system
study long after they had already initiated on ART.
Thus, information on ADRs prior to being enrolled
into the study was missing; using these patients in
the analyses would have biased timing of first ADR.
Other relevant covariates including CD4 count, viral
load and body mass index were not used as these
data had a high rate of missing values.
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lack of adherence data, which has been found to affect the
rate of ADRs due to inadequate treatment uptake [33].
There were very few patients in the study who were started
on ARTs based on the 2010 South African guidelines.
These patients were included under “others” category,
therefore the Tenofovir (TDF) containing combination
was not individually assessed in the analysis. Lastly, several
factors that may predispose patients to adverse reactions of
antiretroviral medications including non-antiretroviral co-
administered medication and treatment; alcoholism and
viral hepatitis co-infection were also not explored [34-36].
Regarding statistical models for recurrent events data
analysis, other models that could have been used include
Anderson and Gill [37] and conditional models of
Prentice, William and Peterson [38] instead of the
WLW marginal model. The specification of the frailty
model that was used for analysis in this paper could
be improved by included time dependant random effects
[22]. In terms of missing data, imputation methods could
have been used on the variables with missing values and
included in the analysis.
Conclusions
This study has shown differential effects of patient’s
age and antiretroviral regimen on the risks of adverse
drug reactions in HIV-infection populations. It has
highlighted the important of optimal drug selection
and monitoring of vulnerable patients in mitigating
the clinical severity of the adverse reactions. Further
analyses using much larger and more complete data
from different settings would be needed to solidify
the findings in this study. Using correlated survival
models is encouraged; however most of these data are
observational in nature, which makes ascertaining
casualty and associations problematic. Thus, to fully
understand the determinants and dynamics of ADRs
in HIV patients on ART, statistical methods including
matching, propensity scores and instrumental variables
techniques and where it is ethically possible, pharmacovigi-
lance clinical trials should be encouraged. ADRs in HIV
patients on ARV treatment are a huge public health
problem in the free-delivery of ARV, especially in the high
HIV epidemic countries of the sub-Saharan, where health
resources are very limited.Ethics approval
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